Viral Genetics, Inc. Appoints C. Everett Koop as Special Advisor to Board of Directors
2008-08-06 12:48:00
Viral Genetics, Inc. Appoints C. Everett Koop as Special Advisor to Board of Directors
Biotech Company Secures Support of Previous U.S. Surgeon General
and Long-Time Advocate of AIDS Research, New Methods of Treatment
AZUSA, Calif.–(EMWNews)–Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that
discovers and develops immune-based therapies, announced today it has
appointed former U.S. Surgeon General, C. Everett Koop, as special
advisor to its board of directors. A long-time advocate for public
health and AIDS research to spearhead advancements in treatment, Dr.
Koop (retired) will advise the board on company decisions surrounding
future research and development of immune-based therapies for HIV/AIDS.
“In our lifetime, there has been no more recognizable United States
Surgeon General than C. Everett Koop. His name and image are synonymous
with leadership and integrity in the medical community. For decades, he
has been instrumental in promoting the acceleration of HIV/AIDS research
to uncover new therapies. We are honored that he has committed to serve
as special advisor to our board,” said Haig
Keledjian, co-founder and CEO of Viral Genetics, Inc.
“I look forward to joining the innovative
efforts of Viral Genetics and its novel approach of immune-based
therapies for the global health problems associated with HIV and AIDS,”
said Dr. Koop.
Charles Everett Koop was born in Brooklyn, New York on October 14, 1916.
He obtained his B.A. degree from Dartmouth College in 1937 and his M.D.
degree from Cornell Medical School in 1941. After interning at the
Pennsylvania Hospital, Dr. Koop pursued postgraduate training at the
University Of Pennsylvania School Of Medicine, Boston Children’s
Hospital and the Graduate School of Medicine at U. of Pennsylvania,
where he obtained a D.Sc. Degree in 1947.
At U. of Penn., Dr. Koop was appointed professor of pediatric surgery in
1959 and then also received a professorship in the department of
pediatrics. From 1948 to 1981, Dr. Koop was also Surgeon-in-Chief at the
Children’s Hospital of Philadelphia where he
was a pioneer in pediatric surgery. He structured an internationally
renowned department that established the first neonatal intensive care
nursery and was a founder of the American Academy of Pediatric Surgeons.
In February 1981, President Reagan appointed Dr. Koop as Deputy
Assistant Secretary for Health. On January 1982, when he was sworn in by
the Senate as U.S. Surgeon General, AIDS was a deadly enigma. At the
direct request of President Reagan in 1986, Dr. Koop prepared the first
national report on AIDS. This explicit, nonjudgmental and monumental
document contributed significantly to providing the first accurate and
comprehensive information on AIDS. In 1988, Dr. Koop wrote
“Understanding AIDS,” a Public Heath Service brochure based on CDC
guidelines, which was sent to all 107 million households in the U.S. It
was the largest mailing ever by the federal government.
“Dr. Koop’s
treatment of HIV / AIDS as a public health issue rather than a moral
issue was a major breakthrough. The report and mailing educated the
public on the magnitude of the epidemic, which garnered support for new
research and methods of treatment,” said
Monica Ord, SVP of corporate development and communications for Viral
Genetics, Inc.
In October 1989, he resigned from office, but his highly regarded
leadership on public health topics such as tobacco, organ
transplantation, AIDS and the rights of the disabled left the Office of
Surgeon General more esteemed than ever before. He has relentlessly
continued to educate the public about health issues through his many
writings and media appearances. Dr. Koop now serves as Senior Scholar of
the C. Everett Koop Institute at Dartmouth Medical School and is a
member of the governing boards of several nationally recognized
health-related organizations.
About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and
develops immune-based therapies for HIV and AIDS using its thymus
nuclear protein compound (TNP). The company recently entered into an
Exclusive License Agreement with the University of Colorado and V-Clip
Pharmaceuticals (a subsidiary of the Company) to license technology
developed by M. Karen Newell, PhD that appears to explain TNP and
provide a means to optimize therapies based on TNP for future clinical
trials. TNP may have other potential applications for other infectious,
autoimmune, and immunological deficiency diseases that the company
intends to study in the future. Viral Genetics believes that its
investigational HIV/AIDS drug based on TNP, called VGV-1, represents a
unique approach to treating HIV due to the apparently novel mechanism,
low toxicity profile, simple dosing regimen, and short-course of
treatment. As a type of immune-based therapy, it focuses on modulating
the immune system to allow the body to fight HIV more efficiently. VGV-1
has been studied in five human clinical trials for the treatment of HIV
/ AIDS. Online at www.viralgenetics.com.
This news release contains forward-looking statements that involve risks
and uncertainties associated with financial projections, budgets,
milestone timelines, clinical development, regulatory approvals, and
other risks described by Viral Genetics, Inc. from time to time in its
periodic reports filed with the SEC. VGV-1 is not approved by the US
Food and Drug Administration or by any comparable regulatory agencies
elsewhere in the world. While Viral Genetics believes that the
forward-looking statements and underlying assumptions contained therein
are reasonable, any of the assumptions could be inaccurate, including,
but not limited to, the ability of Viral Genetics to establish the
efficacy of VGV-1 in the treatment of any disease or health condition,
the development of studies and strategies leading to commercialization
of VGV-1 in the United States, the obtaining of funding required to
carry out the development plan, the completion of studies and tests on
time or at all, and the successful outcome of such studies or tests.
Therefore, there can be no assurance that the forward-looking statements
included in this release will prove to be accurate. In light of the
significant uncertainties inherent in the forward-looking statements
included herein, the forward-looking statements should not be regarded
as a representation by Viral Genetics or any other person that the
objectives and plans of Viral Genetics will be achieved.
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions